- Home
- HURA vs AGEN Comparison
HURA vs AGEN Comparison
Compare HURA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- AGEN
- Stock Information
- Founded
- HURA 2009
- AGEN 1994
- Country
- HURA United States
- AGEN United States
- Employees
- HURA N/A
- AGEN N/A
- Industry
- HURA
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HURA
- AGEN Health Care
- Exchange
- HURA Nasdaq
- AGEN Nasdaq
- Market Cap
- HURA 126.1M
- AGEN 142.8M
- IPO Year
- HURA N/A
- AGEN 2000
- Fundamental
- Price
- HURA $2.59
- AGEN $4.18
- Analyst Decision
- HURA Strong Buy
- AGEN Buy
- Analyst Count
- HURA 2
- AGEN 2
- Target Price
- HURA $11.50
- AGEN $14.50
- AVG Volume (30 Days)
- HURA 214.3K
- AGEN 456.4K
- Earning Date
- HURA 11-13-2025
- AGEN 11-11-2025
- Dividend Yield
- HURA N/A
- AGEN N/A
- EPS Growth
- HURA N/A
- AGEN N/A
- EPS
- HURA N/A
- AGEN N/A
- Revenue
- HURA N/A
- AGEN $101,706,000.00
- Revenue This Year
- HURA N/A
- AGEN $60.49
- Revenue Next Year
- HURA N/A
- AGEN N/A
- P/E Ratio
- HURA N/A
- AGEN N/A
- Revenue Growth
- HURA N/A
- AGEN N/A
- 52 Week Low
- HURA $1.80
- AGEN $1.38
- 52 Week High
- HURA $8.40
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- HURA 45.68
- AGEN 43.11
- Support Level
- HURA $2.38
- AGEN $3.78
- Resistance Level
- HURA $2.66
- AGEN $4.38
- Average True Range (ATR)
- HURA 0.12
- AGEN 0.24
- MACD
- HURA 0.01
- AGEN -0.00
- Stochastic Oscillator
- HURA 42.86
- AGEN 38.24
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).